WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Files An 8-K Regulation FD Disclosure

WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Files An 8-K Regulation FD Disclosure

Story continues below

Item7.01

Regulation FD Disclosure.

From time to time, WAVE Life Sciences Ltd. (the Company),
presents and/or distributes slides and presentations to the
investment community at various industry and other conferences to
provide updates and summaries of its business. On January6, 2017,
the Company updated its corporate presentation, which is
available on the Investors Media section of the Companys website
at http://ir.wavelifesciences.com/. This presentation is attached
as Exhibit 99.1 and is incorporated by reference herein.

The information in Item7.01 of this Form 8-K, including Exhibit
99.1 attached hereto, is intended to be furnished and shall not
be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.


Item8.01
Other Events.

On January6, 2017, the Company issued a press release providing
an update on its pipeline. A copy of the press release is
attached as Exhibit 99.2 to this Form 8-K and is incorporated by
reference herein.


Item9.01
Financial Statements and Exhibits.


(d)
Exhibits


ExhibitNo.


Description

99.1 Corporate presentation of WAVE Life Sciences Ltd., dated as
of January 6, 2017
99.2 Press release issued by WAVE Life Sciences Ltd. on January 6,
2017


About WAVE LIFE SCIENCES LTD. (NASDAQ:WVE)

WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington’s disease, duchenne muscular dystrophy (DMD) and inflammatory bowel disease (IBD). In Huntington’s disease, it has programs that target HTT SNP-1 and HTT SNP-2; in DMD, it targets Exon 51, and in IBD, it targets SMAD7. It has selected lead product candidates in its programs targeting HTT SNP-1 and Exon 51. It has late-stage discovery programs in epidermolysis bullosa simplex, in which it targets KRT14 SNP-1 and KRT14 SNP-2, and in DMD, in which it is focused on an additional DMD target, AcRIIb.

WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Recent Trading Information

WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) closed its last trading session up +0.10 at 27.25 with 213,732 shares trading hands.

An ad to help with our costs